Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up

BACKGROUND: Radioligand therapy (RLT) with (177)Lu-labeled prostate-specific membrane antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with advanced, metastatic castration-resistant prostate cancer (mCRPC). A substantial number of patients, however, are prone to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartrampf, Philipp E., Seitz, Anna Katharina, Weinzierl, Franz-Xaver, Serfling, Sebastian E., Schirbel, Andreas, Rowe, Steven P., Kübler, Hubert, Buck, Andreas K., Werner, Rudolf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525362/
https://www.ncbi.nlm.nih.gov/pubmed/35650263
http://dx.doi.org/10.1007/s00259-022-05853-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525362/
https://www.ncbi.nlm.nih.gov/pubmed/35650263
http://dx.doi.org/10.1007/s00259-022-05853-2

Ejemplares similares